Skip to main content
Assets
CRISPR Therapeutics logo
CRSP.NASDAQ
CRISPR Therapeutics
Health Care · Biotechnology

Gene editing company developing transformative therapies using CRISPR/Cas9 technology for genetic diseases and cancer.

HQ: SwitzerlandListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for CRISPR Therapeutics.

Historical AI Opinions

CRISPR Therapeutics AG (CRSP.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ThinkerAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+219.1%

CRSP.NASDAQ does not currently pay dividends

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.15.9365.28114.62163.96213.31Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$62.5+17.3%Not Generated this time
$71.0+33.3%Not Generated this time
$80.5+51.1%Not Generated this time
$92.1+72.7%Not Generated this time
$105+97.1%Not Generated this time
$118+121.5%Not Generated this time
$132+147.9%Not Generated this time
$145+172.2%Not Generated this time
$158+196.7%Not Generated this time
$170+219.2%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

CRISPR Therapeutics successfully executes a steady, albeit challenging, commercial launch for CASGEVY. Revenue growth is consistent but moderated by logistical and reimbursement hurdles, establishing a solid foundation. The company prudently manages its cash burn while advancing its pipeline. One of its next-generation immuno-oncology candidates shows positive data and progresses to a pivotal trial, de-risking the pipeline and providing a secondary value driver. The in-vivo programs advance methodically, showing promise but not yet reaching a major inflection point within this timeframe. The stock price appreciates, reflecting the gradual transition from a clinical-stage to a commercial-stage company with a validated platform. The valuation grows based on tangible revenue and increasing probability of success for one to two pipeline assets, avoiding both extreme euphoria and excessive pessimism.

2. Scenarios & Signals

2.1. Bull Case

CRISPR Therapeutics experiences a highly successful commercial launch of CASGEVY for sickle cell disease and beta-thalassemia, rapidly exceeding sales forecasts due to strong physician adoption and smooth reimbursement pathways. Concurrently, its immuno-oncology pipeline delivers compelling Phase 2/3 data, leading to at least one new therapy approval within the forecast period. The company's pioneering in-vivo programs, particularly for cardiovascular diseases, demonstrate groundbreaking efficacy and safety, causing a significant re-rating of the entire platform's value. Favorable market conditions for biotech, combined with this strong execution, attract buyout interest from major pharmaceutical players, driving the valuation to levels that reflect a multi-product, gene-editing powerhouse. The company's market capitalization realistically expands as it captures significant share in multi-billion dollar markets previously served by chronic treatments.

2.2. Bear Case

The commercial uptake of CASGEVY proves disappointing, hampered by the high price tag, complex administration logistics, and competition from alternative therapies. Payers impose stringent restrictions, limiting the addressable patient population. Simultaneously, the company's promising pipeline falters, with key immuno-oncology or cardiovascular trials failing to meet primary endpoints or revealing long-term safety concerns inherent to the CRISPR/Cas9 technology. This double blow of commercial underperformance and R&D setbacks forces the company into dilutive financing rounds to sustain operations. Persistent high interest rates and risk-off market sentiment further compress the valuation of pre-profitability biotech firms. The company struggles to move beyond its initial product, and its valuation contracts to reflect a niche, single-product entity with a high-risk, unproven pipeline.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 512Thinking Tokens: 2,690Response Tokens: 8,110Total Tokens: 11,312
Thinker modeThinker · no external search

This Thinker run did not use external web search. The model relied on the supplied research context and its internal reasoning.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.